Nektar Therapeutics Revenue, Profits - NKTR Annual Income Statement

Add to My Stocks
$58.33 $0.02 (0.03%) NKTR stock closing price Sep 18, 2018 (Closing)

Financial analysis of Nektar Therapeutics involves more than just checking the Nektar Therapeutics stock price, by looking at the financial statements of the company in detail. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $307.71M for 2017 impacts the NKTR stock. Investors typically check year over year or quarter over quarter revenue growth. Along with Nektar Therapeutics assets and Nektar Therapeutics free cash flow, Nektar Therapeutics profits as shown in profit and loss statement give key insights about the business. The net profit for 2017 is $-96.69M and the 2017 revenue is $307.71M.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Nektar Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)30.54M30.21M34.1M28.53M38.5M30.42M21.89M25.66M30.94M35.03M
Nektar Therapeutics Gross Profit
Research & Development Expense268.46M203.8M182.78M147.73M190.01M148.67M126.76M108.06M95.1M154.41M
Selling General & Admin Expense68.34M44.27M43.26M40.92M40.53M43.28M46.76M53.56M41M-16.61M
Income Before Depreciation Depletion Amortization-59.64M-112.85M-29.37M-16.48M-120.13M-141.2M-123.93M-28.25M-95.13M-82.65M
Depreciation Depletion Amortization----------
Non Operating Income4.52M2.38M-12.39M-1.12M3.29M1.2M2.37M4.53M62.7M
Interest Expense40.95M42.18M38.9M38.75M40.76M33.54M10.22M11.17M12.17M15.19M
Nektar Therapeutics Pretax Income
Provision for Income Taxes----0.51M2.24M-1.01M--0.25M-0.8M
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-96.69M-153.52M-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M
Extraordinary Items & Discontinued Operations----------
Nektar Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS155.95M139.6M132.46M126.87M115.73M114.82M112.94M94.08M92.77M92.41M
Average Shares used to compute Basic EPS155.95M139.6M132.46M126.87M115.73M114.82M112.94M94.08M92.77M92.41M
Income Before Nonrecurring Items-86.3M-153.52M-81.18M-53.92M-162.01M-170.77M-133.98M-25.71M-102.52M-154.01M
Income from Nonrecurring Items-10.39M-----1.09M--12.23M-69.57M
Nektar Therapeutics Earnings Per Share Basic Net
Nektar Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.55-1.10-0.61-0.42-1.40-1.49-1.19-0.27-1.11-1.67
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Nektar Therapeutics stock analysis involves checking at least a few of the important things like:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that NKTR stock has a topline or revenue of $307.71M for 2017 as per this Nektar Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-96.69M for NKTR stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The NKTR financials along with Nektar Therapeutics historical stock prices provide a lot of details about the firm.

Nektar Therapeutics Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield